| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/12/2003 | US20030108530 Antisense inhibiting melanoma invasion and functional analogs thereof |
| 06/12/2003 | US20030108527 Maturation-promoting agent for immature dendrtic cells |
| 06/12/2003 | US20030108517 Membrane-bound cytokine compositions and methods of modulating an immune response using same |
| 06/12/2003 | US20030108484 Individualization of therapy with antineoplastic agents |
| 06/12/2003 | CA2469385A1 Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them |
| 06/12/2003 | CA2469356A1 Nuclear protein "shoca" - a component of the wnt signalling pathway |
| 06/12/2003 | CA2469349A1 Substituted aryl-cycloalkanes, and use thereof as anticancer agents |
| 06/12/2003 | CA2469227A1 New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| 06/12/2003 | CA2469224A1 Trioxane derivatives |
| 06/12/2003 | CA2469223A1 Trioxane derivatives as antimalaria or anticancer compounds |
| 06/12/2003 | CA2469196A1 Discovery of therapeutic products |
| 06/12/2003 | CA2469193A1 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof |
| 06/12/2003 | CA2469151A1 Immunocytokines with modulated selectivity |
| 06/12/2003 | CA2469119A1 Pharmaceutical compositions comprising active vitamin d compounds |
| 06/12/2003 | CA2469104A1 Minor histocompatibility antigen ha-1: target antigen for immunotherapy of tumors |
| 06/12/2003 | CA2469093A1 A novel herbal chemical composition for the treatment of cancer |
| 06/12/2003 | CA2469078A1 Immunotherapeutic methods and systems |
| 06/12/2003 | CA2468996A1 Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
| 06/12/2003 | CA2468851A1 Gips, a family of polypeptides with transcription factor activity that interact with goodpasture antigen binding protein |
| 06/12/2003 | CA2468839A1 Methods of treating cancer using an fpt inhibitor and anti neoplastic agents |
| 06/12/2003 | CA2468745A1 Induction of apoptosis in cancer cells |
| 06/12/2003 | CA2468701A1 T-bet compositions and methods of use thereof |
| 06/12/2003 | CA2468698A1 Methods and compositions for modulating the immune system and uses thereof |
| 06/12/2003 | CA2468463A1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
| 06/12/2003 | CA2468259A1 Antibody to latent membrane proteins and uses thereof |
| 06/12/2003 | CA2467738A1 Antibodies against carboxic anhydrase ix (ca ix) tumor antigen |
| 06/12/2003 | CA2467435A1 Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors |
| 06/12/2003 | CA2467363A1 Polycistronic expression of antibodies |
| 06/12/2003 | CA2466762A1 Raf-mek-erk pathway inhibitors to treat cancer |
| 06/12/2003 | CA2466751A1 Ep4 receptor agonist, compositions and methods thereof |
| 06/11/2003 | EP1318150A1 Novel crystals of 1,3,4-oxadiazole derivative, process for producing the crystals and medicines containing the same as the active ingredient |
| 06/11/2003 | EP1318149A1 Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing them |
| 06/11/2003 | EP1317927A1 Minor histocompatibility antigen HA-1: target antigen for immunotherapy of tumors |
| 06/11/2003 | EP1317924A1 Kit for reducing aching caused by pde-v inhibitors |
| 06/11/2003 | EP1317669A2 Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators |
| 06/11/2003 | EP1317560A1 Self-rearranging dna vectors |
| 06/11/2003 | EP1317556A1 Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug |
| 06/11/2003 | EP1317554A2 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses tehreof |
| 06/11/2003 | EP1317537A2 G-csf analog compositions and methods |
| 06/11/2003 | EP1317536A2 Tnf receptor-like molecules and uses thereof |
| 06/11/2003 | EP1317531A2 Isolated human phosphatase proteins, nucleic acid molecules encoding them, and uses thereof |
| 06/11/2003 | EP1317527A2 Cellular genes involved in oncogenesis, products of said genes and their diagnostic and therapeutic uses |
| 06/11/2003 | EP1317488A2 Site-specific, antibody-mediated activation of proapoptotic cytokine: amaice (antibody-mediated apoptosis inducing cytokine) |
| 06/11/2003 | EP1317487A2 Caveolin peptides and their use as therapeutics |
| 06/11/2003 | EP1317486A1 Interferon-alpha induced gene |
| 06/11/2003 | EP1317483A2 Variants of allergenic proteins of the group 2 of dermatophagoides |
| 06/11/2003 | EP1317478A2 DISCRIMINATION BETWEEN GnRH-I AND GnRH-II |
| 06/11/2003 | EP1317476A2 Reagents for cell selection and methods of use |
| 06/11/2003 | EP1317470A1 Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy |
| 06/11/2003 | EP1317456A2 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents |
| 06/11/2003 | EP1317454A2 Caspase inhibitors and uses thereof |
| 06/11/2003 | EP1317453A1 Isoxazoles and their use as inhibitors of erk |
| 06/11/2003 | EP1317452A1 Pyrazole compounds useful as protein kinase inhibitors |
| 06/11/2003 | EP1317450A1 Pyrazole compounds useful as protein kinase inhibitors |
| 06/11/2003 | EP1317449A1 Pyrazole compounds useful as protein kinase inhibitors |
| 06/11/2003 | EP1317448A1 Pyrazole compounds useful as protein kinase inhibitors |
| 06/11/2003 | EP1317447A1 Pyrazole compounds useful as protein kinase inhibitors |
| 06/11/2003 | EP1317446A1 Oxindole derivatives |
| 06/11/2003 | EP1317444A1 Pyrazole compounds useful as protein kinase inhibitors |
| 06/11/2003 | EP1317443A2 Chemokine receptor binding heterocyclic compounds |
| 06/11/2003 | EP1317442A1 Quinolinone derivatives as tyrosine kinase inhibitors |
| 06/11/2003 | EP1317433A2 Inhibitors of glycogen synthase kinase 3 |
| 06/11/2003 | EP1317432A1 Piperidine derivatives for use as 2,3-oxidosqualene-lanosterol cyclase inhibitors |
| 06/11/2003 | EP1317428A1 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors |
| 06/11/2003 | EP1317424A2 Polyamine analogues as therapeutic and diagnostic agents |
| 06/11/2003 | EP1317421A1 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 06/11/2003 | EP1317420A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 06/11/2003 | EP1317417A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 06/11/2003 | EP1317413A1 Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same |
| 06/11/2003 | EP1317310A1 Use of serum response factor (srf) modulator for treating srf related diseases |
| 06/11/2003 | EP1317288A2 Method and composition for treating tumors by selective induction of apoptosis |
| 06/11/2003 | EP1317287A2 Polymeric conjugates of antitumor agents |
| 06/11/2003 | EP1317283A2 Tweak receptor agonists as anti-angiogenic agents |
| 06/11/2003 | EP1317282A2 VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS |
| 06/11/2003 | EP1317278A2 Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
| 06/11/2003 | EP1317276A2 Therapeutic use of a recombinant erythropoietin having high activity and reduced side effects |
| 06/11/2003 | EP1317272A2 Composition for improving the cell protection comprising a lipophilic antioxidant an a hydrophilic antioxidant |
| 06/11/2003 | EP1317270A1 Exemestane for the treatment of oestrogen-dependent cancers |
| 06/11/2003 | EP1317260A2 Methods for treating tumors using sulfonyl compounds |
| 06/11/2003 | EP1228077B1 Ruthenium (ii) complexes with high antitumoral and antimetastatic activities |
| 06/11/2003 | EP1156828B1 Combination therapy for lymphoproliferative diseases |
| 06/11/2003 | EP1060161B1 Matrix metalloproteinase inhibitors |
| 06/11/2003 | EP1021413B1 The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| 06/11/2003 | EP0981341B1 Use of betulinic acid derivatives for the treatment and prevention of melanoma |
| 06/11/2003 | EP0910382B1 Squalamine in combination with other anti-cancer agents for treating tumors |
| 06/11/2003 | EP0821586B1 A pharmaceutical composition containing benzimidazole for inhibiting the growth of cancers |
| 06/11/2003 | EP0644900B1 A monoclonal antibody to a human mdr1 multidrug resistance gene product, and its use |
| 06/11/2003 | EP0638119B1 Chimeric receptor genes and cells transformed therewith |
| 06/11/2003 | CN1423748A Solution and crystal structures of MMP-13 active sidte and uses thereof |
| 06/11/2003 | CN1423700A Multifunctional polypeptides comprising a binding site to and epitope of the NKG2D receptor complex |
| 06/11/2003 | CN1423693A Method for the production of vitamin A |
| 06/11/2003 | CN1423660A Antibodies |
| 06/11/2003 | CN1423657A Inter feron-alpha induced gene |
| 06/11/2003 | CN1423647A Beta-alanine derivatives and their use as receptor antagonists |
| 06/11/2003 | CN1423646A Hetero cyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents |
| 06/11/2003 | CN1423645A 维他命d类似物 Vitamin d analogues |
| 06/11/2003 | CN1423642A Oxy-and amino-substituted tetrahydrofurl derivatives with antitumour activity |
| 06/11/2003 | CN1423633A Azetidine derivatives, preparation thereof and pharmaceutical compositions |
| 06/11/2003 | CN1423627A 维生素d类似物 Vitamin d analogues |
| 06/11/2003 | CN1423564A APLIDINE treatment of cancers |